The threat of cancer
has become a multifarious problem worldwide for its fatal effect and recurring
problem. Credit goes to relentless
effort bestowed by Pharmaceutical giants who are keen on extensive research on
quality Carcinogenic medicine. Novartis AG (ADR)(NYSE:NVS) ’s new drug Jakavi,
which is known as a great JAK1/JAK2 inhibitor has received sanction from
European Commission for the medical treatment for myelofibrosis, which is
already detected as a fatal blood cancer.
The approval is all
about encouraging information from the COMFORT program which is known as
extensively as Controlled MyeloFibrosis Study with oral JAK Inhibitor Therapy.
This cpmfort program is segregated in two phases covered by two extensive
studies known as COMFORT I and COMFORT II. MyeloFibrosis Study with oral JAK
Inhibitor Therapy has been recognized as an efficient process for reducing
spleen sizeas well as reduces the intensity of MyeloFibrosis.
Essential medical research and study has revealed
that treatment with Jakavi has been able to reduce spleen size in 35-40% and
this test result has been minutely monitored in COMFORT level-1. The study
duration is 24 weeks and it has proved the efficiency of the said medicine.
Comfort II is the second phase for this study which
has run for 48 weeks: the medicine Jakavi resulted with this long duration is
being widely accepted.
The approval from Europe in nothing new because the
drug Jakavi had already received applause from the Committee for Medicinal
Products for Human Use for investing the pricey drug for its effectivity and
quick turnaround for efficient and side effectless recovery from over shaped
spleen and fallen off for eyebrows.
Being licensed from Incyte
Corporation (INCY)
Janaki has started campaigning for grabbing the market on recognization from US
Food and Drug Administration (:FDA) for Jakavi in November 2011. Phase 3
policies narrats the effect of administration of Jakvi engrossing the patients
with recurring problems. This Jakvi is being hot favorite for treatment of
polycythemia vera.
Jakvi’s
approval has opened a new venue for myelofibrosis as a major
positive step for the treatment of myelofibrosis as a major positive
improvement in medical intervention strategy. With the recommendation, the
medicine will enjoy always better scale of popularty.
No comments:
Post a Comment